Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended): A method for the treatment of ~~of treatment~~ of postlesional diseases of ischemic, traumatic or toxic origin, comprising administering an effective amount of a compound of formula (I) to a human patient in need thereof:



(I)

wherein X represents ~~OH, (C1-5) alkoxy,~~ NH_2, ~~NH-C1-5-alkyl, or N(C1-5 alkyl)2~~ NH-C_{1-3}-alkyl, or $N(C_{1-3}\ alkyl)_2$;

R_1 is a residue derived from ~~one of~~ the amino acid[[s]] Phe~~, Tyr, Trp, Pro,~~ which ~~each~~ may be optionally substituted with one or more methyl groups ~~(C1-5) alkoxy groups, (C1-5) alkyl groups~~ or

one or more halogen atoms, ~~as well as Ala, Val, Leu or~~ ; or is a residue derived from the amino acid Ile;

R_2 is a residue derived from one of the amino acids Gly~~, Ala,~~ or Ile~~, Val, Ser, Thr, Leu and Pro~~;

Y_1 and Y_2 independently from each other represent H or (C_{1-3}) alkyl ~~(C_{1-5}) alkyl~~;

~~R_3 and R_4 independently from each other represent H, OH, (C_{1-5}) alkyl or (C_{1-5}) alkoxy, provided that R_3 and R_4 are not both OH or (C_{1-5}) alkoxy; and~~

~~R_5 represents H, OH, (C_{1-5}) alkyl or (C_{1-5}) alkoxy;~~

or a pharmaceutically acceptable salt thereof.

2. (currently amended): The method according to claim 1, wherein X represents ~~(C_{1-5}) alkoxy, NH_2, NH C_{1-5} alkyl, or $N(C_{1-5}$ alkyl$)_2$~~ NH-C_{1-3}-alkyl, or $N(C_{1-3}$ alkyl$)_2$.

3. (canceled)

4. (canceled)

5. (Currently amended): The method according to claim 1, wherein R_1 is a residue derived from ~~one of~~ the amino acid[[s]] Phe~~, Tyr, Trp, each of~~ which may optionally be substituted with one or more methyl groups ~~a (C_{1-5}) alkoxy groups, (C_{1-5}) alkyl groups~~ or one or more halogen atoms~~, or which is derived from Ile~~.

6. (Currently amended): The method according to claim 5 wherein R_1 is a residue which is derived from Phe, which may optionally be substituted with ~~a (C_{1-5}) alkoxy groups, (C_{1-5}) alkyl groups or~~ one or more halogen atoms.

7. (currently amended): The method according to claim 1, wherein R_2 is a residue which is derived from the amino acid Gly ~~or Ile~~.

8. (Previously presented) The method according to claim 1, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide or a pharmaceutically acceptable salt thereof.